{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:32:27Z","timestamp":1793946747823,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008092","name":"Jinhua City Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373705"],"award-info":[{"award-number":["82373705"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404402"],"award-info":[{"award-number":["82404402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmc.2026.118660","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:22:23Z","timestamp":1775841743000},"page":"118660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of 1H-pyrazolo[3,4-d]pyrimidin-4-ylamine derivatives as potent PI3K\u03b4\/BTK dual-target inhibitors for the treatment of B-cell lymphoma"],"prefix":"10.1016","volume":"138","author":[{"given":"Zunyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youkun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chixiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118660_bb0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coph.2015.05.016","article-title":"Drugging PI3K in cancer: refining targets and therapeutic strategies","volume":"23","author":"Workman","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"10.1016\/j.bmc.2026.118660_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063234","article-title":"Targeting BTK in b cell malignancies: from mode of action to resistance mechanisms","volume":"25","author":"Mouhssine","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118660_bb0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/BJ20090654","article-title":"Epidermal growth factor stimulates translocation of the class II phosphoinositide 3-kinase PI3K-C2beta to the nucleus","volume":"422","author":"Banfic","year":"2009","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.bmc.2026.118660_bb0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1083\/jcb.200907014","article-title":"Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes","volume":"186","author":"Simonsen","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bmc.2026.118660_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101273","article-title":"BTK inhibitors resistance in b cell malignancies: mechanisms and potential therapeutic strategies","volume":"71","author":"Liu","year":"2025","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.bmc.2026.118660_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2014.11.008","article-title":"Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2","volume":"27","author":"Schwartz","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2026.118660_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108242","article-title":"Small-molecule BTK inhibitors: from discovery to clinical application","volume":"157","author":"Tian","year":"2025","journal-title":"Bioorg Chem"},{"issue":"11","key":"10.1016\/j.bmc.2026.118660_bb0040","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-21-3087","article-title":"A phase i study investigating AZD8186, a potent and selective inhibitor of PI3K\u03b2\/\u03b4, in patients with advanced solid tumors","volume":"28","author":"Choudhury","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.bmc.2026.118660_bb0045","article-title":"Association of activated BCR and PI3K pathways with responses and longer PFS to single-agent copanlisib in heavily pretreated patients with indolent and aggressive NHL","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bmc.2026.118660_bb0050","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2026.118660_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177432","article-title":"Targeting PI3K in cancer treatment: a comprehensive review with insights from clinical outcomes","volume":"996","author":"Hossain","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.bmc.2026.118660_bb0060","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118660_bb0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","article-title":"Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway","volume":"142","author":"Polivka","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"51","key":"10.1016\/j.bmc.2026.118660_bb0070","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"issue":"14","key":"10.1016\/j.bmc.2026.118660_bb0075","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cmdc.201600148","article-title":"Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of Copanlisib (BAY 80-6946)","volume":"11","author":"Scott","year":"2016","journal-title":"ChemMedChem"},{"issue":"35","key":"10.1016\/j.bmc.2026.118660_bb0080","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bmc.2026.118660_bb0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Bilanges","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"22","key":"10.1016\/j.bmc.2026.118660_bb0090","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1002\/cncr.30286","article-title":"A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)","volume":"122","author":"Makker","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bmc.2026.118660_bb0095","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11523-017-0530-5","article-title":"A multi-arm phase i study of the PI3K\/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced cancer","volume":"12","author":"Wainberg","year":"2017","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.bmc.2026.118660_bb0100","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.bmcl.2010.03.046","article-title":"Identification of GNE-477, a potent and efficacious dual PI3K\/mTOR inhibitor","volume":"20","author":"Heffron","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.bmc.2026.118660_bb0105","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/bjh.19419","article-title":"Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas","volume":"204","author":"Soumerai","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bmc.2026.118660_bb0110","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1021\/jm501629p","article-title":"Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K\u03b2 and PI3K\u03b4 for the treatment of PTEN-deficient cancers","volume":"58","author":"Bernard","year":"2015","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.bmc.2026.118660_bb0115","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1158\/1078-0432.CCR-17-0676","article-title":"Inhibiting PI3K\u03b2 with AZD8186 regulates key metabolic pathways in PTEN-null tumors","volume":"23","author":"Lynch","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bmc.2026.118660_bb0120","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1021\/jm101582z","article-title":"Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis","volume":"54","author":"Kim","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118660_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1614882","article-title":"Targeting PI3K\u03b4 in cancer: a setback or the end","volume":"15","author":"Hao","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bmc.2026.118660_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"issue":"11","key":"10.1016\/j.bmc.2026.118660_bb0135","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"10.1016\/j.bmc.2026.118660_bb0140","doi-asserted-by":"crossref","first-page":"10530","DOI":"10.1021\/acs.jmedchem.4c00347","article-title":"Designing small molecule PI3K\u03b3 inhibitors: a review of structure-based methods and computational approaches","volume":"67","author":"Yin","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118660_bb0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.120.265538","article-title":"Parsaclisib is a next-generation phosphoinositide 3-kinase \u03b4 inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell malignancy","volume":"374","author":"Shin","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2026.118660_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115331","article-title":"Application of an \u201cinhalation by design\u201d approach to the identification and in-vitro evaluation of novel purine based PI3K\u03b4 inhibitors","volume":"254","author":"Mazzucato","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"W1","key":"10.1016\/j.bmc.2026.118660_bb0155","doi-asserted-by":"crossref","first-page":"W489","DOI":"10.1093\/nar\/gkae380","article-title":"KinomeMETA: a web platform for kinome-wide polypharmacology profiling with meta-learning","volume":"52","author":"Li","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"10.1016\/j.bmc.2026.118660_bb0160","first-page":"8394","article-title":"Computational study on new natural compound inhibitors of Traf2 and Nck-interacting kinase (TNIK)","volume":"14","author":"Ma","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bmc.2026.118660_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108689","article-title":"Fluorenyl-phthalimide hybrids as potent aldose reductase inhibitors with selective anticancer activity: rational design, synthesis, and molecular insights","volume":"163","author":"Gundogdu","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118660_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108788","article-title":"N-substituted phthalimide-carboxylic acid hybrids as dual-targeted aldose reductase inhibitors: synthesis, mechanistic insights, and cancer-relevant profiling","volume":"163","author":"Zognjani","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118660_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108861","article-title":"Chalcone-inspired indole, carbazole, and phenothiazine hybrids as potent aldose reductase inhibitors with selective anticancer potential: rational design, synthesis, and multi-level characterization","volume":"164","author":"G\u00fcle\u00e7","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118660_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118416","article-title":"Phthalimide-benzoic acid hybrids as potent aldose reductase inhibitors: synthesis, enzymatic kinetics, and in silico characterization","volume":"131","author":"Hoti","year":"2025","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118660_bb0185","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1039\/D4MD00617H","article-title":"Novel benzenesulfonamides containing a dual triazole moiety with selective carbonic anhydrase inhibition and anticancer activity","volume":"16","author":"Buza","year":"2024","journal-title":"RSC Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:02:02Z","timestamp":1793944922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"alternative-id":["S0968089626001161"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118660","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 1H-pyrazolo[3,4-d]pyrimidin-4-ylamine derivatives as potent PI3K\u03b4\/BTK dual-target inhibitors for the treatment of B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118660"}}